192 results about "Hemoglobin H" patented technology

The invention discloses a neonatal jaundice health management system based on big data, and belongs to the technical field of jaundice health management, and the system specifically comprises the steps: collecting the transdermal jaundice measurement value, hemoglobin concentration, day age and weight data of a neonate through a data collection module; an individualized drift index is calculated based on the hemoglobin concentration and the day age data through a physiological parameter calibration module; inputting the transdermal jaundice measurement numerical value and the individualized drift index into a dynamic correction model through a dynamic prediction analysis module to generate a serum bilirubin prediction numerical value; a time sequence data processing module is used for smoothing the predicted numerical value and calculating the variable quantity of adjacent time points; constructing trend indexes and generating serum bilirubin change trend data through a trend analysis and detection module; and finally, generating a health management scheme based on the threshold level and the trend change point through an intelligent decision module. According to the invention, effective assessment and personalized management of the neonatal jaundice risk are realized.

The invention discloses an fNIRS adaptive feedback emotion cognition cooperative training device and method, and relates to the technical field of emotion disorder cognition training. The device comprises a data acquisition module used for acquiring an original dual-wavelength light intensity signal from a brain; the data processing module is used for performing multi-stage preprocessing on the original dual-wavelength light intensity signal; the neural feedback module is used for calculating a multi-dimensional evaluation index according to the hemoglobin concentration data and adjusting a difficulty level and a feedback threshold value of a training task by using a dynamic threshold value control algorithm; the training module is used for training participants based on the emotion stimulation task and the cognitive training task; and the evaluation module is used for performing training evaluation according to the comparison result of the comprehensive performance score and the feedback threshold. Brain function equipment is closely combined with cognitive training and emotion stimulation tasks, dynamic evaluation and real-time feedback are added for traditional tasks, and through the brain network analysis technology, accurate evaluation of the user training effect is achieved.

The invention relates to the technical field of medical informatics, in particular to an AI-based intelligent early warning system for hyperuricemia male reproductive metabolism abnormality. The system comprises a memory and a processor, and the processor executes a computer program stored in the memory to realize the following steps: acquiring uric acid data, waistline data, glycosylated hemoglobin data and reproductive index data of a target male; combining the uric acid fluctuation abnormality degree, the multi-dimensional blood glucose abnormality expression degree and the movement rule expression degree of each stage to obtain the reproduction metabolism abnormality degree; according to the relative relationship between the reproductive index data and the corresponding standard range, obtaining the abnormal performance degree of the reproductive index; integrating the reproductive metabolism abnormality degree and the reproductive index abnormality expression degree to obtain a multi-dimensional feature linkage reproductive metabolism expression comprehensive evaluation degree of the target male; and according to the comprehensive evaluation degree of the multi-dimensional feature linkage reproductive metabolism performance, whether early warning is carried out is judged. According to the invention, the accuracy and credibility of intelligent early warning of the risk of abnormal male reproductive metabolism of hyperuricemia are improved.

The invention provides a recognition and early warning method and device for irritable hyperglycemia, electronic equipment and a storage medium, and is applied to the technical field of medical data processing. According to the method, data type information (including FreeStyle LibreH dynamic blood glucose and glycosylated hemoglobin data), influence factor data (improved and preset irritable hyperglycemia index and the like) and abnormal state information (fasting interference and detection difference) are taken; acute-stage and chronic-stage average blood glucose basic data are generated through preprocessing. The index weight is enhanced and improved by means of a dynamic fusion engine, the probability is predicted by combining space-time correlation analysis and binary logistic regression, and the abnormal characteristics are obtained by comparing the difference of the AUC by adopting Delog test. The multi-modal features are processed to obtain an identification result, clinical indexes screened by LASSO are fused, index differences are compared to generate risk influence factors, finally, a dynamic early warning result is generated based on a space-time correlation early warning engine and a multi-target strategy, and accurate identification and early warning are achieved.

The invention discloses a method for detecting a fatigue state based on a multi-modal data fusion technology, and the method comprises the following steps: S1, collecting multi-modal training data through a sleep deprivation experiment, and carrying out the training of a model. Comprising fNIRS, ECG, PPG, GSP and Resp, hemoglobin concentration data, obtained through a fNIRS headband, of the forehead lobe of the brain is obviously related to fatigue, data of electrocardio, pulse waves, skin electricity and respiratory waves are obtained through an electrocardio sensor (pectoral girdle), a PPG bracelet, a GSR ring and a respiratory wave (Resp) sensor (waistband), the data collected by different devices are objective, the defects of psychological experiment methods are effectively overcome, and the psychological experiment accuracy is improved. And different modalities can provide complementary information, and even capture the features of the target from multiple angles.

An electronic device comprises a housing configured to contact a user's skin, an optical transmitter array, an optical receiver, a memory element and a processing element. The optical transmitter array outputs a plurality of optical signals that pass through the user's skin, each of the plurality of optical signals having one of three wavelengths. The optical receiver receives the optical signals and generates corresponding photoplethysmogram (PPG) signals. The memory element stores absorption constants for deoxyhemoglobin blood content, oxyhemoglobin blood content and glycated hemoglobin blood content, each absorption constant associated with one of the first wavelength, the second wavelength or the third wavelength. The processing element determines a glycated hemoglobin blood level for the user based on a ratio of a determined glycated hemoglobin blood content to a sum of determined deoxyhemoglobin blood content, a determined oxyhemoglobin blood content and a determined glycated hemoglobin blood content.

The invention provides a plateau hypoxic encephaledema early warning system, which comprises a first acquisition module configured to emit ultrasonic waves to at least two tangent planes of a first area to obtain an ultrasonic image reflected after being transmitted by an eyeball, and determining the diameter of an optic nerve sheath after first preprocessing; the second acquisition module is configured to emit a near-infrared signal source to a second area to obtain a spectral image reflected after transcranial transmission, and absorption spectrums of oxyhemoglobin and deoxidized hemoglobin are obtained after second preprocessing; the data processing module is configured to obtain the optic nerve sheath diameter and the absorption spectrum and determine a first influence factor and a second influence factor about the optic nerve sheath diameter and the absorption spectrum; and the early warning module is configured to give an alarm if the first influence factor and the second influence factor exceed a preset threshold value under a first preset condition. Early warning and monitoring of encephaledema are achieved through multi-mode monitoring.

The invention discloses an AI intelligent multi-terminal adaptive non-invasive hemoglobin detector and a detection method, and the detector comprises a configuration module which is used for transmitting combined light with a specific wavelength to penetrate a fingernail bed of a user when the fingertip of the user is placed in an accommodation cavity; the image acquisition module is integrated in the intelligent terminal and is used for shooting a multiband image reflected by a fingernail bed when the fingertip of the user is placed in the accommodating cavity; the transmission module is used for transmitting the multiband image to the processing module; and the processing module is internally provided with a deep learning spectral feature regression model and is used for extracting features related to the hemoglobin concentration from the multiband image, carrying out regression calculation and outputting a quantitative hemoglobin concentration value. Optical signals carry complete concentration related information after penetrating through the fingernail bed, so that the detection precision is improved; image acquisition is integrated on an intelligent terminal commonly used by a user, the use threshold is reduced through multi-terminal adaptation, the accuracy of data feature extraction is improved based on a deep learning spectral feature regression model, and then the accuracy of a detection result is improved.

The present invention concerns the use of a molecule chosen from a globin, a globin protomer or an extracellular hemoglobin of Annelids, for treating and / or preventing at least one complement-activation associated disease, preferably ischemia / reperfusion injury and / or transplant rejection.

To provide genome editing systems, reagents and methods for treatment of hemoglobinopathies.SOLUTION: Genome editing systems are provided, comprising: a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a BCL11A gene, a BCL11a enhancer, or a HFPH region; and a Cas9 molecule.SELECTED DRAWING: None

The application discloses a hemolysis analyzer based on an integrated optical waveguide sensor and a preparation method thereof, and comprises an integrated photon waveguide, a nano filter and a micro-fluidic channel, wherein the integrated photon waveguide is a single waveguide with a middle spiral type and coupling gratings on both sides. The hemolysis analyzer fully utilizes the advantages of high sensitivity and small volume of the integrated optical waveguide sensor, and realizes sample-free preparation by combining the methods of instantaneous absorption and hemoglobin filtration, and can quickly and accurately detect hemolysis and the degree of hemolysis.

The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and / or phosphatidylserine content. The present disclosure describes technologies useful for the treatment of inflammatory diseases, disorders, or conditions (e.g., atherosclerosis).

The invention belongs to the technical field of medicines, and relates to an application of a pharmaceutical composition in preparation of medicines for preventing and / or treating type II diabetes mellitus. The invention provides an application of a pharmaceutical composition in preparation of a medicine for preventing and / or treating type II diabetes mellitus. The pharmaceutical composition comprises the following components: ginsenoside Rk1, ginsenoside Rg5, ginsenoside Rg3, ginsenoside Rh4, ginsenoside Rk3, a ginseng ethanol-water extract and a pharmaceutically acceptable carrier. The pharmaceutical composition component provided by the invention can effectively reduce blood sugar and / or reduce the glycosylated hemoglobin level, and prevent and / or treat type II diabetes mellitus.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.

The invention relates to the technical field of biological medicines, in particular to a Chinese wolfberry all-component mixture and application thereof in treatment of diabetes mellitus. The Chinese wolfberry all-component mixture is prepared through the following steps: S1, taking Chinese wolfberry fruits, performing continuous extraction for three times, combining extracting solutions obtained by the three times of extraction, performing filtration, and performing concentration so as to obtain a Chinese wolfberry fruit extract; s2, taking leaf buds, carpopodium and branches of the Chinese wolfberry, performing continuous extraction for three times, combining the three extraction solutions, filtering, and concentrating to obtain a leaf bud / carpopodium / branch extract of the Chinese wolfberry; and S3, mixing the Chinese wolfberry fruit extract obtained in the step S1 with the Chinese wolfberry leaf bud / fruit stem / branch extract obtained in the step S2, filtering, performing graded purification by adopting an ultrafiltration method, intercepting 20-100kDa components, and sterilizing to obtain a Chinese wolfberry all-component mixture. The Chinese wolfberry all-component mixture disclosed by the invention can be used for remarkably reducing a plurality of biochemical index levels such as fasting blood-glucose, glycosylated hemoglobin, triglyceride and extremely low density lipoprotein of a mouse with type 2 diabetes mellitus.

The application discloses a kind of fNIRS adaptive feedback emotion cognitive collaborative training device and method, it is related to emotional disorder cognitive training technical field.The device includes: data acquisition module, for obtaining original double-wavelength light intensity signal from brain;Data processing module, for the original double-wavelength light intensity signal is carried out multistage pretreatment;Neural feedback module, for calculating multidimensional evaluation index according to hemoglobin concentration data, and using dynamic threshold control algorithm adjusts the difficulty level and feedback threshold of training task;Training module, for training participant based on emotional stimulation task and cognitive training task;Evaluation module, for training evaluation according to comprehensive performance score and feedback threshold comparison result.The present application closely combines brain function equipment with cognitive training and emotional stimulation task, adds dynamic evaluation and real-time feedback to traditional task, and realizes the precise evaluation of user training effect by brain network analysis technology.

Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.

The present invention relates to a composition for diagnosing immunodeficiency or a method for providing information for diagnosis thereof. By using the composition and the method according to one aspect, it is possible to simply and effectively diagnose immune-deficient conditions such as immunosuppression or immune paralysis.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention relates to the technical field of neurological rehabilitation, in particular to a transcranial direct current closed-loop regulation and control method based on near-infrared brain oxygen real-time feedback, which comprises the following steps: collecting brain oxygen baseline signals of each region of the whole brain, calculating the mean value and the standard deviation of each brain region, and establishing a whole brain blood oxygen regulation and control threshold matrix of sub-regions and sub-parameters; dynamically adjusting the core target brain region, and adjusting the sampling frequency and the single detection duration according to the fluctuation frequency of the oxyhemoglobin concentration of the core target brain region; according to the signal fluctuation frequency, continuously adapting the detection parameters, and combining the comparison result of the core characteristic parameters and the whole brain blood oxygen regulation threshold matrix, optimizing the transcranial direct current regulation parameters, and outputting optimized data; by means of the mode, dynamic adaptation of the detection parameters and the signal fluctuation characteristics is carried out, and regulation and control collaboration is improved.

The present invention relates to a method and apparatus for determining the activity of clotting factors in diluted capillary whole blood, citrated whole blood and citrated plasma. The invention also includes the detection of hemoglobin content in the whole blood sample to correct for clotting time so that the clotting time values are not affected by hemoglobin and hematocrit.

The present application belongs to the field of photochemical therapy, and particularly relates to a method for photochemical treatment of riboflavin based on multi-wavelength LED and application thereof in treatment of graft-versus-host disease. The present application selects different wavelength LED combinations as light sources to optimize the riboflavin photochemical method, controls the light intensity at 1000-25000 μW / cm², controls the irradiation time at 5-15 minutes, and controls the riboflavin concentration at 20-150 μM, thereby significantly improving the photochemical reaction effect. The method can efficiently induce PBMC apoptosis in a plasma environment, significantly reduces the levels of key pro-inflammatory cytokines such as TNF-α, IL-6 and IFN-γ, and has no significant influence on platelets, hemoglobin and blood clotting function, thereby providing a safe and controllable new cell preparation method for GVHD treatment.

The present invention relates to a novel complement C5-binding antibody and a use thereof. The complement C5-binding antibody according to the present invention can significantly inhibit complement C5 activity by targeting the MG1 domain of the beta chain of complement C5, and thus can be used for preventing or treating various complement-related diseases including myasthenia gravis, age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria.

The application relates to the technical field of medical information processing, and discloses a method and system for dynamically evaluating post-renal biopsy occult bleeding risk based on multi-source data fusion, wherein the method comprises the following steps: constructing a standardized uniform observation vector sequence; constructing a short-time instant risk model; constructing a mechanism to establish a long-time lag risk transfer model; generating a hierarchical treatment decision and a review scheduling plan; gain correcting the risk probability; and outputting a final occult bleeding risk grade. Compared with the scheme for postoperative bleeding risk in the prior art, which only performs static risk evaluation based on a single time section index, especially in the case that postoperative vital signs are temporarily stable but there is delayed hemoglobin decline, the technical problem that the continuous prediction of the risk transfer process of'short-time stability-long-time lag deterioration' cannot be realized is solved. Since the time-varying state transfer probability matrix is introduced in the application, and the risk transfer acceleration is determined, the sensitivity of postoperative risk identification is improved.

In the field of gene therapy, a major hurdle is the design and identification of constructs and gene therapy vectors providing therapeutic effects while displaying satisfactory safety profiles. In the treatment of Diamond-Blackfan Anemia (DBA), therapies alleviating several crucial anemia symptoms, such as blood or bone marrow cellularity, hemoglobin levels, erythrocytes levels, or platelet levels, while showing satisfactory safety profiles remain a challenge. The present invention provides constructs encoding ribosomal protein genes involved in DBA, such as genes encoding RPS19, RPS17, RPS24, RPS10, RPL35a, RPL11, RPS26, and RPL5, vectors, methods, cells, and medical uses thereof, addressing these challenges and finding particular applications in the field of autologous cell therapy treatment of DBA. Further, the present invention provides a non-genotoxic conditioning protocol for preparing a subject prior to cell therapy treatment for DBA using construct of the present invention.

The invention provides a biomarker composition and an application thereof. The biomarker composition comprises the following proteins: MMP12, UMOD, HbA1c, FGF9, NINJ1 and PRSS8. According to the biomarker composition provided by the invention, through combination of matrix metalloproteinase 12, uromodulin, glycosylated hemoglobin, FGF9, NINJ1 and serine protease 8, the problem of lack of a specific marker for aortic wall structure damage in the prior art is solved.

The system comprises a laminated 5 diagnostic strip including a backing layer (105), an absorbent pad layer (106) configured for controlled capillary transport of milk, and a reagent deposit layer (107) defining multiple spatially separated dry reagent zones. The reagent zones include a pH indicator zone (101), a leukocyte esterase detection zone (102), a hemoglobin detection zone (103), and a nitrite detection zone (104), each adapted 10 for operation in the milk matrix. A calibrated sample application point (108) receives a predefined volume of untreated milk and fluidically communicates the sample to the reagent zones via the absorbent pad layer. Colorimetric reactions develop in a result window area (109), enabling simultaneous visual interpretation without analytical instruments, typically within three minutes. The invention further 15 includes a moisture-controlled storage container comprising desiccant elements (204, 205), a reference color chart (208), and a calibrated pipette (209), ensuring reagent stability and standardized use.

The invention discloses a spectrum system in beauty based on a special spectrum. The ACNE acne wavelength is (400-600) nm + (800-1200) nm; wherein 400-600 nm is used for superficial layer sterilization, and 800-1200 nm is used for deep oil control; the wavelength special for the VASCULAR blood vessel is 530 nm to 650 nm + 900 nm to 1200 nm; wherein the wavelength of 530-650 nm covers a hemoglobin absorption peak, and the wavelength of 900-1200 nm covers a secondary absorption peak; a full closed loop of precise treatment, comfortable experience and postoperative stability maintenance is realized, and the system is very suitable for the requirements of the modern medical beauty market on layered anti-aging and comfortable treatment.

This invention provides CRISPR / CAS-related compositions and methods for treating β-abnormal hemoglobinopathy. [Solution] A guide RNA (gRNA) molecule is provided, which includes a targeting domain complementary to a target domain located within a region selected from the group consisting of HBG1, HBG2, and HBG1 and HBG2 regulatory regions, wherein the targeting domain includes a specific nucleotide sequence.